机器人辅助支气管镜活检周围型肺病灶的前瞻性多中心TARGET试验
TARGET试验为多中心前瞻性单臂研究,纳入679例需支气管镜诊断的8–50 mm肺病灶患者行机器人辅助支气管镜(RAB)活检;主要终点(需干预的气胸、出血或呼吸衰竭)发生率为3.8%,RAB到达病灶率98.7%,严格标准下诊断率61.6%,恶性病变灵敏度78.8%。
要点
- RAB对周围型肺病灶活检的主要安全终点事件发生率为3.8%。
- RAB到达病灶率98.7%,径向支气管内超声确认病灶位置率91.7%。
- 严格报告标准下诊断率61.6%,恶性病变灵敏度78.8%。
核心结论
- RAB引导下周围型肺病灶采样安全,结果优于大型非机器人支气管镜研究。
研究设计与样本
- 多中心、前瞻性、单臂研究,21个中心纳入715例,679例符合标准并接受RAB。
- 纳入年龄>21岁、需支气管镜诊断的8–50 mm肺病灶患者。
主要发现
- 平均年龄68.7岁,女性55.4%,当前/既往吸烟者77.5%。
- 病灶平均大小20.9 mm(范围7.0–63.0),距胸膜表面中位距离5 mm(IQR 0–16)。
- 实体病灶587例(86.6%),位于肺外侧三分之二593例(87.5%)。
- 主要终点事件26例(3.8%):气胸19例、出血7例、呼吸衰竭0例。
- 12个月内恶性患病率64.1%,严格标准下诊断率61.6%,恶性灵敏度78.8%。
关键数值与推荐
- 主要终点为器械或操作相关事件:需干预的气胸、需干预的出血或呼吸衰竭。
- RAB到达病灶670/679例(98.7%),径向支气管内超声确认607/662例(91.7%),经支气管镜采样675/679例(99.4%)。
临床怎么用
- RAB可用于周围型肺病灶的微创活检,需关注气胸和出血风险。
- 诊断率与恶性灵敏度数据可供临床决策和患者沟通参考。
局限性
- 单臂设计,无随机对照。
- 多数为白人及吸烟人群,外推需谨慎。
- 严格的诊断率定义可能低估真实诊断效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It remains challenging to safely and reliably biopsy peripheral pulmonary lesions (PPLs). Robotic-assisted bronchoscopy (RAB) is gaining adoption for navigation to PPLs. However, evidence from large studies remains limited. RESEARCH QUESTION: What is the clinical safety, navigational success, and diagnostic yield of RAB for biopsy of PPLs in a broad range of patients in a real-world setting? STUDY DESIGN AND METHODS: This multicenter, prospective, single-arm study enrolled patients aged > 21 years with 8- to 50-mm lung lesions requiring bronchoscopic diagnosis. The primary end point was the incidence of the following device- or procedure-related events: (1) pneumothorax requiring intervention; (2) bleeding requiring intervention; or (3) respiratory failure. Secondary end points included individual components of the primary end point, procedure time, pneumothoraces, radial probe endobronchial ultrasound confirmation, conversion to an alternative biopsy procedure, complications, and diagnostic yield. RESULTS: Among 715 patients at 21 sites, 679 met study criteria and underwent RAB (mean age 68.7 years; 55.4% female; 86.5% White; 77.5% with current/past tobacco use). Mean (range) lesion size was 20.9 (7.0-63.0) mm; median (interquartile range) distance from the pleural surface was 5 (0-16) mm. Most lesions were solid (n = 587 [86.6%]) and within the outer two-thirds of the lung (n = 593 [87.5%]). The primary end point was observed in 26 (3.8%) patients (19 pneumothorax, 7 bleeding, and 0 respiratory failure). Users reported that RAB reached the lesion in 670 (98.7%) of 679 cases, and lesion location was confirmed with radial probe endobronchial ultrasound in 607 (91.7%) of 662 cases; sampling through the bronchoscope was performed in 675 (99.4%) of 679 cases. Prevalence of malignancy was 64.1% through 12 months. Adjudicated diagnostic yield was 61.6% when calculated with the American Thoracic Society/American College of Chest Physicians (CHEST) definition for strict reporting criteria. Sensitivity for malignancy was 78.8%. INTERPRETATION: This multicenter prospective study of RAB-to our knowledge, the largest to date-showed that RAB-guided sampling of PPLs is safe and compares favorably to results from sizable non-robotic bronchoscopy studies. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT04182815; URL: www. CLINICALTRIALS: gov.
引用
- Murgu S, Chen AC, Gilbert CR, et al. A Prospective, Multicenter Evaluation of Safety and Diagnostic Outcomes With Robotic-Assisted Bronchoscopy: Results of the Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung (TARGET) Trial. Chest. 2025. PMID: 40300665. doi:10.1016/j.chest.2025.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。